Union européenne - estonien - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - sclerosis multiplex, relapsing-remitting - immunosupressandid - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Union européenne - estonien - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomide - sclerosis multiplex, relapsing-remitting - immunosuppressants, valikuline immunosuppressants - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Estonie - estonien - Ravimiamet

sandoz pharmaceuticals d.d. - teriflunomiid - õhukese polümeerikattega tablett - 14mg 84tk; 14mg 28tk

Estonie - estonien - Ravimiamet

stada arzneimittel ag - teriflunomiid - õhukese polümeerikattega tablett - 14mg 28tk; 14mg 84tk

Estonie - estonien - Ravimiamet

krka, d.d., novo mesto - teriflunomiid - õhukese polümeerikattega tablett - 14mg 84tk; 14mg 14tk; 14mg 98tk; 14mg 28tk; 14mg 30tk

Estonie - estonien - Ravimiamet

gedeon richter plc. - teriflunomiid - õhukese polümeerikattega tablett - 14mg 28tk; 14mg 14tk; 14mg 98tk; 14mg 84tk

Estonie - estonien - Ravimiamet

zentiva k.s. - teriflunomiid - õhukese polümeerikattega tablett - 14mg 14tk; 14mg 28tk; 14mg 84tk

Union européenne - estonien - EMA (European Medicines Agency)

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastilised ained - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

Estonie - estonien - Ravimiamet

norameda uab - teriflunomiid - õhukese polümeerikattega tablett - 14mg 28tk

Estonie - estonien - Ravimiamet

sia elvim - leflunomiid - õhukese polümeerikattega tablett - 10mg 30tk